|
UNITED STATES |
||
|
SECURITIES AND EXCHANGE COMMISSION |
||
|
Washington, D.C. 20549 |
||
|
FORM 8-K |
||
|
CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
||
|
July 7, 2020 |
||
|
Date of Report (Date of Earliest Event Reported) |
||
|
ULTRALIFE CORPORATION |
||
|
(Exact name of registrant as specified in its charter) |
||
|
Delaware |
000-20852 |
16-1387013 |
|
(State of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
2000 Technology Parkway, Newark, New York 14513 |
||
|
(Address of principal executive offices) (Zip Code) |
||
|
(315) 332-7100 |
||
|
(Registrant’s telephone number, including area code) |
||
|
None |
||
|
(Former name or former address, if changed since last report) |
||
|
Securities registered pursuant to Section 12(b) of the Act: |
||
|
Common Stock, $0.10 par value per share |
ULBI |
NASDAQ |
|
(Title of each class) |
(Trading Symbol) |
(Name of each exchange on which registered) |
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |
||
|
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
||
|
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
||
|
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
||
|
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |
||
Item 8.01 Other Events
On July 7, 2020, Ultralife Corporation (“Ultralife” or the “Company”) issued a press release to announce that due to the ongoing public health impact of the coronavirus (COVID-19) pandemic and out of an abundance of caution, the location of the Annual Meeting of Stockholders of Ultralife to be held on July 22, 2020 at 9:00 AM Eastern Time will be changed to the Company’s Newark, NY headquarters located at 2000 Technology Parkway, Newark, NY 14513.
The information set forth in this Form 8-K and the attached exhibit is being furnished to and not filed with the Securities and Exchange Commission and shall not be deemed as incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing.
Item 9.01 Financial Statements, Pro Forma Financials and Exhibits
(d) Exhibits.
|
Exhibit Number |
Exhibit Description |
||
|
99.1 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: July 7, 2020 |
ULTRALIFE Corporation |
|
|
By: |
/s/ Philip A. Fain |
|
|
Philip A. Fain |
||
|
Chief Financial Officer and Treasurer |
Exhibit 99.1
Ultralife Corporation Announces Change in Location of
Annual Meeting of Shareholders
NEWARK, N.Y. – July 7, 2020 -- Ultralife Corporation (NASDAQ: ULBI) today announced that due to the ongoing public health impact of the coronavirus (COVID-19) pandemic and out of an abundance of caution, the location of the Annual Meeting of Shareholders to be held on July 22nd at 9:00 AM Eastern Time will be changed to the Newark, NY headquarters of Ultralife located at 2000 Technology Parkway, Newark, NY 14513. The Meeting was originally scheduled to be held at The Westin Crystal City in Arlington, VA. Except for the change in location, all other details of the Annual Meeting, including the proposals to be voted at the Meeting, remain unchanged.
As described in the proxy materials for the Annual Meeting previously distributed, shareholders are entitled to vote at the Annual Meeting if they were a shareholder at the close of business on May 26, 2020, the record date. The Meeting will begin promptly at 9:00 AM Eastern Time.
For additional information regarding how shareholders may vote in advance of or at the Annual Meeting, please refer to Ultralife’s proxy materials filed with the U.S. Securities and Exchange Commission, which can also be accessed on the Company’s website at www.ultralifecorporation.com. Please note that the proxy card included with the proxy materials will not be updated to reflect the change in location and may continue to be used to vote shares in connection with the Annual Meeting.
About Ultralife Corporation
Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government, defense and commercial customers across the globe.
Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.
Company Contact:
Ultralife Corporation
Philip A. Fain
(315) 210-6110
pfain@ulbi.com
Investor Relations Contact:
LHA
Jody Burfening
(212) 838-3777
jburfening@lhai.com